News

Alzheimer’s trial to test drug on people without symptoms to see if it can be prevented

Healthy middle-aged people deemed to be at higher risk of developing condition among those eligible to participate People without memory loss will be offered an experimental Alzheimer’s drug that could stop the development of the condition before dementia symptoms emerge. Healthy middle-aged people deemed to have a higher risk of developing the condition will be eligible to participate in the trial, which is being run by an NHS trust as part of an international clinical trial aiming to prevent dementia. Continue reading...

Targeted Reduction of PTBP1 Reverses Cognitive Impairment in a Mouse Model of Alzheimer's Disease

Many of the more sophisticated forms of medicine, including gene therapies and immunotherapies, are challenging to deliver to the brain. At the very least there are far fewer practical options for delivery, and it is possible that none of that that exist fit a given desired use case. The blood-brain barrier stands in the way of intravenous injection as a path for most approaches, blocking passage of most cells and molecules from circulation to brain tissue. While direct injection into the brain or into reservoirs of cerebrospinal fluid can be achieved, they are sufficiently invasive and challenging to rule out commonplace use. The brain is made up of many different cell types, and more sophisticated approaches will want specificity to regions or cell types. Small […]

Stanford scientists discover a seafood that can reverse signs of aging

A substance found in edible sea squirts appeared to reverse several signs of aging in older mice. Plasmalogen supplements improved memory and learning, strengthened connections between brain cells, reduced inflammation, and even helped the mice grow thicker, darker hair. Researchers believe the compounds may encourage brain regeneration and protect aging synapses.

China approves Leqembi subcutaneous autoinjector for early Alzheimer’s

China’s National Medical Products Administration approved the subcutaneous autoinjector formulation of LEQEMBI (lecanemab) as an initiation treatment for mild cognitive impairment due to alzheimer’s disease and mild alzheimer’s disease dementia. The approved regimen is 500 mg once weekly, administered as two consecutive 250 mg injections, and patients may switch between intravenous and subcutaneous administration during […] The post China approves Leqembi subcutaneous autoinjector for early Alzheimer’s appeared first on Longevity.Technology.

Suggesting ERBB4 Overexpression as an Important Mechanism in Alzheimer's Disease

Researchers here suggest that increased ERBB4 expression in neurons is an important driving mechanism in the onset and progression of Alzheimer's disease. One has to be cautious with such findings, even given the effort made by the researchers to show that human data is compatible with the hypothesis, because the mouse models of Alzheimer's disease in which these sorts of discovery are made are very artificial. Mice do not normal exhibit anything like Alzheimer's disease, so the models induce forms of dysfunction that result in something resembling Alzheimer's in humans. The model embodies assumptions about relevant mechanisms that may not be correct, and this is one of the reasons why progress towards therapies has been slow and painful. Single-nucleus RNA-sequencing analysis identified the emergence of […]

‘If you can’t understand what sex is, it’s irrelevant if you seem to be enjoying it’: how Queen at Sea upended the dementia drama

Lance Hammer’s first film in 18 years is a heart-wrenching masterpiece about family, mental decline and sexual consent. He and supporting actor Juliette Binoche discuss how they brought unabashed realism to a condition rarely seen on screen The first time we see Martin and Leslie, the elderly couple at the centre of Lance Hammer’s wrenching new film, Queen at Sea, they are walking together up a set of stone steps: one of their regular outings, we assume, in days filled with pottering and quiet companionship. They have their backs to us, and we can’t see their destination beyond a bleached sky that fills the top half of the screen. Symbolically, it may be deemed a bit on the nose: two people near the end of their lives, moving gently towards the white light of oblivion. There’s a whiff of sentimentality about it. But any doubts about this story’s willingness to confront dif

Senescent Microglia Secrete DLK1, Which Causes Dysfunction in the Aging Brain

Senescent cells accumulate with age in tissues throughout the body, disrupting tissue structure and function with inflammatory secretions. The growing burden of senescent cells is an important contributing cause of degenerative aging. A cell becomes senescent in response to damage induced by some form of stress, or more often when a somatic cell reaches the Hayflick limit on cellular replication. In youth senescent cells are efficiently cleared by the immune system, but immune system aging allows senescent cells to linger and grow in number. Immune cells themselves are prone to reaching the Hayflick limit and entering replicative senescence because they respond to a variety of issues with greater replication to multiply their efforts. Research into neurodegenerative conditions and the state of the aging brain has […]

Annovis sails past enrollment goal on Alzheimer’s

850 patients signed up for an Alzheimer’s trial needing 760. For a biotech betting everything on one pill, that’s the good kind of surprise. Trial enrollment is the part of drug development nobody writes headlines about. It’s slow, unglamorous and it’s also where a lot of promising drugs quietly die, not because the science failed, […] The post Annovis sails past enrollment goal on Alzheimer’s appeared first on Longevity.Technology.

LifespanningRx launches peptide explorer for clinician-guided reviews

LifespanningRx has launched the Peptide Explorer, an online educational tool designed to help users organize health goals and explore up to three peptide therapy candidates before clinical evaluation. The company says the experience takes about five minutes and uses a structured questionnaire covering areas such as energy and metabolism, body composition, recovery, healthy aging, cognitive […] The post LifespanningRx launches peptide explorer for clinician-guided reviews appeared first on Longevity.Technology.

One immune switch may help drive aging across the body

Aging may be partly fueled by immune cells losing their ability to clear away damaged, inflammation-promoting cells. Blocking a single receptor restored that cleanup process in mice, reducing inflammation and helping their organs, muscles, and memory remain remarkably youthful.

Sex hormones in the nucleus incertus: a novel perspective on sex/gender differences in memory and mood dysfunction in Alzheimer’s disease

About 60% of the individuals living with Alzheimer’s disease (AD) in the United States are women. Increasing evidence points to a role for sex hormones, especially estrogen, in making women more vulnerable to AD than men. Several brainstem signaling pathways, as well as multiple neuropeptide modulators and their receptors, are implicated in AD pathology and therapeutic possibilities. However, there is limited research evaluating how the modulatory effects of sex hormones on mood and cognition interact with these brainstem systems. This review seeks to examine possible connections between the nucleus incertus (NI) relaxin-3/relaxin-family peptide receptor 3 (RLN3/RXFP3) system and sex hormone influences in AD to encourage further investigation into how sex hormones may modulate this pathway and contribute to sex differences in disease risk and progression. Understanding how hormone-based

Correction: Long non-coding RNAs in glial cells: key drivers of neuroinflammation in cognitive disorders

Multidimensional iron dysmetabolism and gut-brain axis interactions in restless legs syndrome: from peripheral deficiency to central dysregulation

Restless Legs Syndrome (RLS) is a sensorimotor neurological disorder characterized by an irresistible urge to move the lower limbs. Although traditional paradigms attribute its pathogenesis to peripheral iron deficiency, many clinically diagnosed patients present with normal peripheral iron indicators yet exhibit central iron homeostatic dysregulation. This discrepancy highlights a distinct decoupling between peripheral iron stores and central iron availability. The RLS-associated iron metabolic impairment is inherently a complex pathological network orchestrated by multidimensional processes, including intestinal absorption, systemic distribution, blood-brain barrier (BBB) transport, and intracellular utilization. Crucially, gut dysbiosis-induced low-grade enterogenous inflammation may activate the IL-6/hepcidin pathway, thereby sequestering systemically available iron; this mechanism r

Joint network analysis of non-motor symptoms and quality of life in patients with Parkinson’s disease

BackgroundNon-motor symptoms (NMS) are highly prevalent in Parkinson’s disease (PD) and are major determinants of declining quality of life (QoL), yet traditional statistical approaches are insufficient to capture the complex interactions between NMS and QoL. Network analysis offers a promising alternative for exploring these interactions.ObjectiveTo construct a joint network of non-motor symptoms (NMS) and quality of life (QoL) in patients with Parkinson’s disease (PD), identify core and bridge nodes, and inform precision nursing interventions.MethodsA convenience sample of 342 PD patients was recruited between January and June 2026 from the PD specialty outpatient clinic and neurology inpatient wards of a tertiary specialized hospital in Tianjin, and investigated using the Non-Motor Symptoms Scale (NMSS) and the Parkinson’s Disease Questionnaire-39 (PDQ-39). A joint network model was c

Retraction: Violation of the ultrastructural size principle in the dorsolateral prefrontal cortex underlies working memory impairment in the aged common marmoset (Callithrix jacchus)

Inflammation and delirium in critically Ill patients: a review

The high prevalence and adverse impact of delirium in critically ill patients necessitate a deeper understanding of its mechanisms. This review explores the pivotal interplay between systemic inflammation and delirium, examining how insults like age, pain and surgery orchestrate neuroinflammation and delirium through microglial activation and blood-brain barrier disruption. Our synthesis identifies a spectrum of inflammatory and neuronal injury biomarkers with prognostic value and evaluates the burgeoning field of anti-inflammatory pharmacotherapy. We conclude that bridging this mechanistic knowledge to clinical practice via biomarker-driven trials is essential for developing effective interventions against delirium.

Engram cell vulnerability in neurodegeneration: from mechanistic insights to therapeutic horizons

Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD) share progressive memory impairment, yet their upstream pathologies differ. This review synthesizes evidence across these disorders to frame memory decline through engram ensembles and proposes an excitability-vulnerability tradeoff, in which the physiological requirements for engram function, including elevated excitability, synaptic plasticity, and coordinated network activity, also increase sensitivity to synaptic stress, network disruption, and inflammatory perturbations. We summarize disease-related pathological cascades. To date, AD has the most robust body of direct experimental evidence linking pathology to impaired engram function. Solid experimental findings demonstrate that amyloid-β (Aβ)/tau causes hippocampal engram inaccessibility in AD. For PD and HD, infere

Alzheimer’s may leave a mark on the brain long before plaques appear

Brain changes associated with Alzheimer’s may begin at least seven years before amyloid plaques become detectable with current PET scans. Researchers uncovered the signal by tracking healthy older adults with repeated brain imaging over nearly 20 years. The discovery could help scientists identify Alzheimer’s earlier and suggests that important disease processes may start before visible plaque buildup.

Different Parts of the Brain Exhibit Different Vulnerability to Synucleinopathy

Parkinson's disease and Lewy body dementia are synucleinopathies, characterized by the spread of misfolded α-synuclein through the central nervous system. The presence of misfolded α-synuclein provokes harmful changes in cell behavior and ultimately cell death in important populations of neurons. Researchers here explore differences in the vulnerability of different parts of the brain to the pathology produced by misfolded α-synuclein. They conclude that more complex parts of the brain, characterized by increased mitochondrial activity and greater connectivity between neurons, are more fragile in the face of the pathological mechanisms of syncleinopathy. A total of 89 patients with dementia with Lewy bodies and 89 matched controls underwent T1-weighted brain MRI. Scans were processed to generate surface-based cortical thickness maps. Regional cortical thickness estimates, after slice-by-

Oligomerix appoints new interim CEO to advance Alzheimer’s drug pipeline

Oligomerix appointed Cara Cassino, M.D., as interim president and chief executive officer on 31 August 2026. According to the company, Cassino has 25 years of clinical drug development and commercialization experience across large pharmaceutical and biotech firms and more than 25 FDA and EMA drug approvals. Cassino has held senior roles at Boehringer Ingelheim and […] The post Oligomerix appoints new interim CEO to advance Alzheimer’s drug pipeline appeared first on Longevity.Technology.

Blood cells replace the immune cells of the ageing human brain

ImmunoBrain’s immune reset shows promise in Alzheimer’s

Nature Medicine publication and late-breaking data put ImmunoBrain’s checkpoint immunotherapy and its clean safety profile in the spotlight. While much of Alzheimer’s drug development chases the disease’s hallmark proteins directly, ImmunoBrain Checkpoint is making its case from a different angle entirely: strengthening the body’s own immune system so it can help protect and repair the […] The post ImmunoBrain’s immune reset shows promise in Alzheimer’s appeared first on Longevity.Technology.

Reaching 90 without dementia doesn’t mean you’re in the clear

A study of people over 90 found that dementia risk remains strongly shaped by sex, race and genetics, with women and black participants facing notably higher risks. Intriguingly, some people stayed cognitively healthy despite carrying major risk factors, potentially offering clues to how the brain can resist dementia deep into old age.

Canada recommends public funding for Alzheimer’s drug Leqembi

Biogen Inc. stock drew renewed attention after a Canadian advisory committee issued a final positive recommendation supporting public reimbursement of Leqembi, developed with partner Eisai, for Canadians with mild cognitive impairment or mild dementia due to early Alzheimer’s disease. The recommendation could lead to provincial and territorial funding decisions that expand access in Canada. According […] The post Canada recommends public funding for Alzheimer’s drug Leqembi appeared first on Longevity.Technology.

Oligomerix appoints new interim CEO to lead Alzheimer’s drug development

Oligomerix has appointed Dr. Cara Cassino as interim president and chief executive officer as the privately held biotech moves from discovery toward clinical development of its lead Alzheimer’s candidate. Cassino has served on the Oligomerix board since July 2025 and brings about 25 years of clinical drug development and commercialization experience that includes senior roles […] The post Oligomerix appoints new interim CEO to lead Alzheimer’s drug development appeared first on Longevity.Technology.

Structural and functional alterations of posterior cingulate cortex subregions in successful cognitive aging

Successful cognitive aging (SCA) describes the preservation of cognitive abilities into advanced age, but its neural basis remains incompletely understood. Metabolic and pathological evidence implicates the posterior cingulate cortex (PCC) as a key region supporting cognitive resilience. However, functionally distinct PCC subregions have rarely been examined using complementary structural, microstructural, and functional imaging measures. In this cross-sectional secondary analysis of publicly available Human Connectome Project in Aging data, we identified 29 adults aged at least 80 years who met successful cognitive aging criteria based on episodic memory and executive function. We selected 29 adults with normal aging (NA) group and 29 middle-aged adults (MA) group matched for sex and education, yielding 87 participants. We combined structural MRI, neurite orientation dispersion and dens

Author Correction: Characterizing the metabolomes of microglia, astrocytes and neurons in ageing and Alzheimer’s brains

Advances in the treatment of age-related hearing loss: from molecular mechanisms to targeted interventions

Age-related hearing loss (ARHL) is the most common sensory disorder in older adults. Current hearing interventions, including hearing aids and cochlear implants, face limitations in accessibility and adherence. Therefore, efforts have been devoted to elucidating the molecular mechanisms underlying cochlear aging and identifying effective therapeutic targets for ARHL. This review summarizes several molecular mechanisms implicated in cochlear aging and ARHL, including autophagy dysregulation, oxidative stress, stereocilia degeneration, and dysregulation of mitochondrial dynamics. We further discuss recent advances in potential therapeutic targets and intervention strategies associated with these pathways, and provide theoretical support for targeted interventions for ARHL.

FDA clears software that quantifies amyloid in Alzheimer’s

NeuroQuant clearance automates amyloid quantification for Alzheimer’s imaging, trading radiologist’s judgment call for standardized number. Reading a brain scan for Alzheimer’s has long come down to a radiologist’s trained eye and best guess. That guesswork just got a software co-pilot with the FDA’s sign-off attached. Cortechs.ai announced on 18 August that its NeuroQuant PET platform […] The post FDA clears software that quantifies amyloid in Alzheimer’s appeared first on Longevity.Technology.

Mission Therapeutics, NeuraLight partner on Parkinson’s biomarkers

Mission Therapeutics and NeuraLight have partnered to deploy NeuraLight’s eye-movement-derived brain function biomarkers across Mission’s multinational MTX325 trial in Parkinson’s disease, spanning clinical sites in the UK, Europe and Australia. NeuraLight’s platform will provide objective, repeatable measures intended to quantify neural pathway function and detect subtle changes that conventional clinical scales may miss. MTX325 is […] The post Mission Therapeutics, NeuraLight partner on Parkinson’s biomarkers appeared first on Longevity.Technology.

Inflammation and neuropsychiatric symptoms in Parkinson's disease: a genetic association

BackgroundThere has been some evidence that neuroinflammation is involved in Parkinson's disease (PD) and in psychiatric disorders.ObjectiveTo explore the effects of IL-1β rs16944 on PD patients' neuropsychiatric symptoms.MethodsTwo hundred and eighty-one consecutive PD patients underwent a neurological and neuropsychological evaluations, which included: Unified Parkinson's Disease Rating Scale, Schwab and England Activities of Daily Living scale, Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease—Anytime Short, Hospital Anxiety and Depression Scale and Dementia Rating Scale-2. The Neuropsychiatric Inventory (NPI) was also applied to patients' caregivers/informants. In addition to IL-1β rs16944, DRD3 rs6280 and GRIN2B rs7301328 were also genotyped. Non-parametric group comparisons and linear and logistic regressions were used for data analyses.ResultsThe IL-1β rs1694

A validated workflow for paired total and small RNA sequencing from low-input submandibular gland biopsy specimens in de novo Parkinson’s disease patients

Parkinson’s disease (PD) is characterized by progressive α-synuclein aggregation, yet the molecular mechanisms underlying this process remain incompletely understood. Transcriptomic analyses may provide important insights into the RNA-mediated regulation of PD pathogenesis, but studies of affected brain tissue are limited by the inaccessibility of living brain tissue and post-mortem RNA degradation. The submandibular gland (SMG), which exhibits α-synuclein pathology comparable to that of the substantia nigra, represents a clinically accessible peripheral tissue for investigating disease-associated transcriptomic alterations. However, ultrasound-guided core needle biopsy yields only a limited amount of tissue, making comprehensive RNA sequencing technically challenging. Here, we present and validate a workflow for paired total RNA and small RNA sequencing from low-input SMG biopsy specime

Short-term environmental enrichment modulates brain region-specific redox responses in adolescent female mice

BackgroundEnvironmental enrichment (EE) is a non-pharmacological intervention known to enhance neuroplasticity and resilience. However, studies of EE on brain redox balance have focused predominantly on males and single regions, leaving the developing female brain and region-specific responses largely uncharacterized. This study investigated the effects of a three-week EE protocol on oxidative balance in the hippocampus, hypothalamus, and brainstem of adolescent female C57BL/6 mice.MethodsLipid peroxidation was measured by thiobarbituric acid reactive substances (TBARS), and protein oxidation by carbonyl content. The enzymatic antioxidant system was evaluated through the activities of superoxide dismutase (SOD), catalase (CAT), and glutathione S-transferase (GST). Non-enzymatic antioxidant defenses included quantification of reduced glutathione (GSH), oxidized glutathione (GSSG), the GSH

Interpretable machine learning model based on multimodal MRI radiomics for Alzheimer's disease diagnosis

ObjectiveAlzheimer's disease (AD), the most common neurodegenerative disorder, is a leading cause of cognitive impairment and dementia in older adults. This study aimed to develop an interpretable machine learning model using multimodal MRI radiomics for the diagnosis of Alzheimer's disease.Materials and methodsA total of 110 subjects (48 AD, 62 healthy control subjects) underwent 3D T1WI, DWI, and T2WI scans. Radiomics features were extracted from eight AD-related brain regions and selected using a three-step approach: variance thresholding, independent t-test, and LASSO–all conducted strictly within the training cohort. Logistic regression (LR) and random forest (RF) models were constructed for single-sequence and combined-sequence data. Model performance was evaluated using ROC analysis, calibration curves, and decision curve analysis. SHapley Additive exPlanations (SHAP) was applied

Your sleep may be hiding an early clue to Alzheimer’s

Frequent micro-awakenings during sleep were linked to higher genetic risk for Alzheimer’s in healthy middle-aged adults who had no symptoms. The discovery raises the possibility that subtle changes during sleep could offer an early warning signal years before memory problems appear.

AstronauTx turns sleep into new dementia target

AstronauTx has exercised its Saniona option, advancing a sleep-focused neurodegeneration candidate toward IND-enabling studies. Sleep has become one of the most talked-about levers in longevity science, credited with everything from metabolic health to cognitive resilience. AstronauTx, a UK biotech founded by SV Health’s Dementia Discovery Fund, is now translating that interest into a drug pipeline. […] The post AstronauTx turns sleep into new dementia target appeared first on Longevity.Technology.

BTT begins first human safety trial using heat therapy for ALS

BTT Medical Institute, in collaboration with BTT Corp., has initiated a first-in-human clinical and biological safety trial (ClinicalTrials.gov Identifier: NCT07564440) to evaluate induced hyperthermia delivered by the Abreu BTT 700 Temperature Management System, a noninvasive computerized, brain-guided platform that raises body temperature into a controlled fever range through cyclical thermal modulation. The trial, approved by […] The post BTT begins first human safety trial using heat therapy for ALS appeared first on Longevity.Technology.

AlzeCure to showcase Alzheimer’s, pain research at Pareto Healthcare Conference

AlzeCure will present at the Pareto Securities 17th Annual Healthcare Conference in Stockholm on 2 September, with CEO Martin Jönsson scheduled to deliver a presentation and answer questions. The presentation and one-on-one meetings are planned at Hotel At Six, Brunkebergstorg 6, with the company scheduling the session for 17:05-17:25 CEST and saying the presentation will […] The post AlzeCure to showcase Alzheimer’s, pain research at Pareto Healthcare Conference appeared first on Longevity.Technology.

Astragaloside IV attenuates hypoxia-reoxygenation-induced endothelial senescence and vascular inflammation by modulating the NOTCH1/VCAM-1 axis

ObjectiveAlzheimer's disease (AD) progression involves cerebral microvascular endothelial cell senescence induced by brain hypoperfusion, which contributes to blood-brain barrier (BBB) dysfunction. While Notch1 signaling is known to exacerbate endothelial senescence and neuroinflammation via vascular cell adhesion molecule-1 (VCAM-1), the mechanism by which it mediates hypoxia-induced endothelial aging in AD remains unclear. Furthermore, although Astragaloside IV (AS-IV) has been shown to alleviate cerebral hypoperfusion in AD, whether it acts by directly modulating the Notch1/VCAM-1 axis is unknown. This study aimed to determine whether AS-IV mitigates endothelial senescence and AD pathology by modulating the Notch1/VCAM-1 pathway.MethodsTranscriptomic analysis of AD patient data and network pharmacology identified NOTCH1 as a key target. Molecular docking and 100-ns molecular dynamics

Closing the gap in Alzheimer’s disease research through the Sex | Gender in Neurodegeneration Consortium